P-dude, can't agree with you more! The real business question is- how in the hell can anyone justify the local buildout of the country with dozens of specialists carrying a bag of one drug with such a restrictive label? Amarin the company simply cannot afford this strategy. They really need to run a skeleton crew (say 3 people) while shopping the company aggressively to big pharma. The idea of developing various regions to enhance value has run its course.
I always thought single payer systems like Europe care more about longer term financial prudence but am thinking in Europe governments change almost as quickly as people change insurance in the US… one notable example for longer term chronic management are the statins…but there the buzz was so great you could not not pay for it.